Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Visceral Medicine
|
August 11, 2020
Immunotherapy in Gastrointestinal Cancers
Melanie Güthle, Thomas Ettrich, Thomas Seufferlein
Clinical Nuclear Medicine
|
October 18, 2022
203 Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor
Dirk Müller, Hendrik Herrmann, Michael K Schultz, et al.
BMC Cancer
|
August 20, 2011
Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population
Julia C Stingl, Thomas Ettrich, Rainer Muche, et al.
Visceral Medicine
|
March 15, 2021
Computed Tomography-Based Tumor Heterogeneity Analysis Reveals Differences in a Cohort with Advanced Pancreatic Carcinoma under Palliative Chemotherapy
Jochen Paul Steinacker, Nora Steinacker-Stanescu, Thomas Ettrich, et al.
Trials
|
July 12, 2020
Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial
Siri Göpel, Wolfgang Bethge, Peter Martus, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 24, 2022
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
Sylvie Lorenzen, Peter Thuss-Patience, Claudia Pauligk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2025
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial
Ulrich Güller, Stefanie Hayoz, Daniel Horber, et al.
BMC Cancer
|
June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
International Journal of Cancer
|
June 10, 2026
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, et al.
BMJ Open
|
September 10, 2025
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
Conrad Rauber, Maria Paula Roberti, Maria Jgt Vehreschild, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Visceral Medicine
|
August 11, 2020
Immunotherapy in Gastrointestinal Cancers
Melanie Güthle, Thomas Ettrich, Thomas Seufferlein
Clinical Nuclear Medicine
|
October 18, 2022
203 Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor
Dirk Müller, Hendrik Herrmann, Michael K Schultz, et al.
BMC Cancer
|
August 20, 2011
Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population
Julia C Stingl, Thomas Ettrich, Rainer Muche, et al.
Visceral Medicine
|
March 15, 2021
Computed Tomography-Based Tumor Heterogeneity Analysis Reveals Differences in a Cohort with Advanced Pancreatic Carcinoma under Palliative Chemotherapy
Jochen Paul Steinacker, Nora Steinacker-Stanescu, Thomas Ettrich, et al.
Trials
|
July 12, 2020
Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial
Siri Göpel, Wolfgang Bethge, Peter Martus, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 24, 2022
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
Sylvie Lorenzen, Peter Thuss-Patience, Claudia Pauligk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2025
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial
Ulrich Güller, Stefanie Hayoz, Daniel Horber, et al.
BMC Cancer
|
June 4, 2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Joseph Tintelnot, Eray Goekkurt, Mascha Binder, et al.
International Journal of Cancer
|
June 10, 2026
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, et al.
BMJ Open
|
September 10, 2025
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
Conrad Rauber, Maria Paula Roberti, Maria Jgt Vehreschild, et al.
Page
of 2